PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE B
Post# of 301275
REGULATED INFORMATION
GHENT, Belgium, 6 July 2017 - Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"), that it received a notification of shareholdings from Bank of America Corporation on 5 July 2017.
Bank of America Corporation (taking into account the holdings of its subsidiary undertakings) notified Ablynx that they have dropped below the 5% threshold as of 28 June 2017 and now hold a total of 3,038,688 shares with voting rights, representing 4.97% of the current 61,133,199 outstanding Ablynx shares (versus 5.24% notified previously).
The notified details are presented below:
| Name of select subsidiaries of Bank of America Corporation | % of shares and voting rights | % of shares and voting rights held through financial instruments | Total of both | |||
| Shares | Voting rights | Shares | Voting rights | Shares | Voting rights | |
| Merrill Lynch Professional Clearing Corp. | 4.96% | 4.96% | 4.96% | 4.96% | ||
| Merrill Lynch Financial Markets, Inc. | 0.01% | 0.01% | 0.01% | 0.01% | ||
| TOTAL | 4.96% | 4.96% | 0.01% | 0.01% | 4.97% | 4.97% |
Merrill Lynch Professional Clearing Corporation and Merrill Lynch Financial Markets, Inc. are controlled by Bank of America Corporation. Bank of America Corporation is not a controlled entity.
Full versions of all transparency notifications are available on Ablynx website, under the section Investors .
About Ablynx
Ablynx is a biopharmaceutical company engaged in the development of Nanobodies , proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has more than 45 proprietary and partnered programmes in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease. The Company has collaborations with multiple pharmaceutical companies including AbbVie; Boehringer Ingelheim; Eddingpharm; Merck & Co., Inc., Kenilworth, New Jersey, USA; Merck KGaA; Novartis; Novo Nordisk and Taisho Pharmaceuticals. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com .
For more information, please contact Ablynx: Dr Edwin Moses CEO t: +32 (0)9 262 00 07 m: +32 (0)473 39 50 68 e: edwin.moses@ablynx.com
Lies Vanneste Director Investor Relations t: +32 (0)9 262 01 37 m: +32 (0)498 05 35 79 e: lies.vanneste@ablynx.com
Follow us on Twitter @AblynxABLX
Ablynx media/analyst relations FTI Consulting: Julia Phillips, Brett Pollard, Mo Noonan t: +44 20 3727 1000 e: ablynx@fticonsulting.com
Attachments:
(0)
(0)